Antibodies against heterogeneous nuclear ribonucleoprotein K in patients with cardiac allograft vasculopathy

Heterogeneous Nuclear Ribonucleoprotein K Autoantibodies in Patients who Suffered Severe Traumatic Brain Injury

“…In the previous study we describe that antibodies against hnRNPK were associated with a vascular endothelial damage in heart transplanted patients [9]. Similarly, in the current study, TBI patients who developed autoantibodies after trauma are probably due to vascular endothelium damage.…”

“…Samples were immediately centrifuged, frozen at -80°C and were stored for later analysis. Anti-hnRNPK IgG antibodies were detected by ELISA using hnRNPK recombinant protein previously purified in our laboratory [9]. Recombinant hnRNP-K protein, once affinity-purified by polyhistidine-tag, was plated at 2 µg/ml (in 0.1 mol/liter carbonate-bicarbonate buffer, p H 9.5) onto a polystyrene flat-bottom ELISA plate (Nunc, Roskilde, Denmark) and incubated for 16 hours at 4°C.…”

“…In the previous study, we identify a new antigen that seems to be associated with endothelial damage, related auto-antigens with a significative increase in the production of antibodies against heterogeneous nuclear Ribonucleoprotein K (hnRNPK), and a type of AECA, in heart transplanted patients who developed Cardiac Allograft Vasculopathy (CAV) [9]. This protein, is a member of the hnRNP family which has several different cellular roles including transcription, mRNA shuttling, RNA editing and translation.…”

MicroRNAs in heart transplant recipients

“…Причиной данных процессов является совокупное поражение эндоте-лия, индуцированное аллоиммунными реакциями и неиммунологическими факторами, такими как ишемическо-реперфузионное поражение, вирусные инфекции и метаболические расстройства [46,49]. Для ранней диагностики васкулопатии сердечного трансплантата могут использоваться как метаболи-ческие показатели -отношение триглицеридов к ли-попротеинам высокой плотности [50,51], уровень инсулина в плазме [52,53], -так и иммунологичес-кие/воспалительные -уровни донор-специфичных анти-HLA антител [54], антител против гетероген-ного ядерного рибонуклеопротеина К [55], С-реак-тивного белка [56,57], VCAM-1 (молекулы адгезии сосудистой клетки-1) [57,58] и циркулирующего C-X-C фрагмента хемокина 12 [59]. Однако про-гностическая способность этих биомаркеров вне связи с развившимися клиническими проявлени-ями достоверно не установлена.…”

Moving beyond HLA: A review of nHLA antibodies in organ transplantation

“…In heart transplant patients, there is a reported association of nHLA antibodies against myosin and vimentin with cardiac allograft vasculopathy (CAV) [38, 39]. In another study of heart transplant recipients, levels of anti-heterogeneous nuclear ribonucleoprotein K antibodies (anti-hnRNP-K antibodies) four years post-transplant were found to be statistically significantly associated with CAV disease [40]. Additionally, another study of 616 adult cardiac transplant recipients found that patients with pre-transplant nHLA IgM antibodies had significantly lower survival rates at 1, 2, 5, 10 year post-transplant and their presence in the pre-transplant sera could be a major risk factor for allograft failure [15].…”